[1]张牧秋,古俊楠,刘 瑜,等.NOACS治疗房颤合并急性冠脉综合征的研究[J].医学信息,2019,32(13):28-31.[doi:10.3969/j.issn.1006-1959.2019.13.010]
　ZHANG Mu-qiu,GU Jun-nan,LIU Yu,et al.Study of NOACS in the Treatment of Atrial Fibrillation Complicated with Acute Coronary Syndrome[J].Journal of Medical Information,2019,32(13):28-31.[doi:10.3969/j.issn.1006-1959.2019.13.010]
点击复制

NOACS治疗房颤合并急性冠脉综合征的研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年13期
页码:
28-31
栏目:
综述
出版日期:
2019-07-01

文章信息/Info

Title:
Study of NOACS in the Treatment of Atrial Fibrillation Complicated with Acute Coronary Syndrome
文章编号:
1006-1959（2019）13-0028-04
作者:
张牧秋; 古俊楠; 刘 瑜; 王建强; 李 超
首都医科大学第四临床医学院，北京 100191
Author(s):
ZHANG Mu-qiu; GU Jun-nan; LIU Yu; WANG Jian-qiang; LI Chao
The Fourth Clinical Medical College,Capital Medical University,Beijing 100191,China
关键词:
心房颤动; 急性冠脉综合征; 新型口服抗凝药
Keywords:
Key words：Atrial fibrillation; Acute coronary syndrome; New oral anticoagulants
分类号:
R541.4；R541.75
DOI:
10.3969/j.issn.1006-1959.2019.13.010
文献标志码:
A
摘要:
心房颤动合并急性冠脉综合征的发病率逐年增高，其治疗方案越来越受到人们的关注。由于冠脉血栓和房颤血栓的形成机制不同，因此抗栓治疗的难点在于如何平衡出血和血栓风险，以减少并发症的发生。近年来，新型口服抗凝药物的上市为抗栓治疗提供了新的思路，本文将对新型口服抗凝药物在房颤合并急性冠脉综合征患者抗栓治疗方面的相关研究进行综述。
Abstract:
Abstract：The incidence of atrial fibrillation complicated with acute coronary syndrome has increased year by year, and its treatment plan has attracted more and more attention. Because of the different mechanisms of coronary thrombosis and atrial fibrillation, the difficulty in antithrombotic therapy is how to balance the risk of bleeding and thrombosis to reduce the incidence of complications. In recent years, the launch of new oral anticoagulant drugs has provided new ideas for antithrombotic therapy. This article will review the related research on new oral anticoagulant drugs in the treatment of atrial fibrillation with antithrombotic therapy in patients with acute coronary syndrome.

参考文献/References:

[1]Schnabel RB,Yin X,Gona P,et al.50 year trends in atrial fibrillation prevalence,incidence, risk factors,and mortality in the Framingham Heart Study:a cohort study[J].Lancet,2015,386(9989):154-162. [2]Fluschnik N,Becher PM,Schnabel R,et al.Anticoagulation strategies in patients with atrial fibrillation after PCI or with ACS:The end of triple therapy[J].Herz,2018,43(1):20-25. [3]Fake A,Ranchord A,Harding S,et al.Triple Therapy Versus Dual Antiplatelet Therapy for Patients with Atrial Fibrillation and Acute Coronary Syndromes:A Systematic Literature Review[J].Curr Cardiol Rev,2017,13(4):325-333. [4]De Luca L,Casella G,Rubboli A,et al.Recent trends in management and outcome of patients with acute coronary syndromes and atrial fibrillation[J].Int J Cardiol,2017(248):369-375. [5]梁峰,胡大一,方全,等.2017ACC非瓣膜病房颤患者围手术期抗凝管理决策的专家共识[J].中国循证心血管医学杂志,2017,9(11):1281-1287. [6]Dalal J,Bhave A,Oomman A,et al.The Indian consensus guidance on stroke prevention in atrial fibrillation:An emphasis on practical use of nonvitamin K oral anticoagulants[J].Indian Heart J,2015,67(2):S13-S34. [7]Harder S,Graff J.Novel oral anticoagulants:clinical pharmacology,indications and practical considerations[J].European Journal of Clinical Pharmacology,2013,69(9):1617-1633. [8]中华心血管病杂志编辑委员会血栓栓塞防治循证工作组.达比加群酯用于非瓣膜病心房颤动患者卒中预防的临床应用建议[J].中华心血管病杂志,2014,42(3):188-192. [9]Dewilde WJ,Oirbans T,Verheugt FW,et al.Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention:an open-label,randomised,controlled trial[J].The Lancet,2013,381(9872):1107-1115. [10]Braun OO,Bico B,Chaudhry U,et al.Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome[J].Thromb Res,2015,135(1):26-30. [11]Lamberts M,Gislason GH,Olesen JB,et al.Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention[J].J Am Coll Cardiol,2013,62(11):981-989. [12]Rubboli A,Schlitt A,Kiviniemi T,et al.One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting:an analysis of the AFCAS registry[J].Clin Cardiol,2014,37(6):357-364. [13]Hori M,Matsumoto M,Tanahashi N,et al.Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study[J].Circ J,2012,76(9):2104-2111. [14]Hori M,Connolly SJ,Zhu J,et al.Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation[J].Stroke,2013,44(7):1891-1896. [15]Xu H,Ruff CT,Giugliano RP,et al.Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation:Analysis From the ENGAGE AF-TIMI48 Trial[J].J Am Heart Assoc,2016,5(2):e002587. [16]Gibson CM,Mehran R,Bode C,et al.Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI[J].N Engl J Med,2016,375(25):2423-2434. [17]Cannon CP,Bhatt DL,Oldgren J,et al.Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation[J].N Engl J Med,2017,377(16):1513-1524. [18]Lopes RD,Vora AN,Liaw D,et al.An open-Label,2×2 factorial,randomized controlled trial to evaluate the safety of apixaban vs.vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial[J].Am Heart J,2018(200):17-23. [19]Vranckx P,Lewalter T,Valgimigli M,et al.Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention(PCI)with stent placement:Rationale and design of the ENTRUST-AF PCI trial[J].Am Heart J,2018(196):105-112. [20]Lip GY,Wang KL,Chiang CE.Non-vitamin K antagonist oral anticoagulants(NOACs)for stroke prevention in Asian patients with atrial fibrillation:time for a reappraisal[J].Int J Cardiol,2015(180):246-254. [21]Freedman B,Potpara TS,Lip GY.Stroke prevention in atrial fibrillation[J].Lancet,2016,388(10046):806-817. [22]January CT,Wann LS,Calkins H,et al.2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation[J].Circulation,2019:R665. [23]Steffel J,Verhamme P,Potpara TS,et al.The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation:executive summary[J].Kardiol Pol,2018,76(9):1283-1298. [24]Neumann FJ,Sousa-Uva M,Ahlsson A,et al.2018 ESC/EACTS Guidelines on myocardial revascularization[J].Kardiol Pol,2018,76(12):1585-1664. [25]Chiang CE,Okumura K,Zhang S,et al.2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation[J].J Arrhythm,2017,33(4):345-367. [26]Fiedler KA,Maeng M,Mehilli J,et al.Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation:The ISAR-TRIPLE Trial[J].J Am Coll Cardiol,2015,65(16):1619-1629. [27]Mehta SR,Bainey KR,Cantor WJ,et al.2018 Canadian Cardiovascular SocietyCanadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy[J].Can J Cardiol,2018,34(3):214-233. [28]Sarafoff N,Martischnig A,Wealer J,et al.Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation[J].J Am Coll Cardiol,2013,61(20):2060-2066. [29]Jackson LN,Ju C,Zettler M,et al.Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy:A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study[J].JACC Cardiovasc Interv,2015,8(14):1880-1889.

相似文献/References:

[1]姜亦瑶,王 凯,施 超.心肌纤维化引发心房颤动的研究进展[J].医学信息,2018,31(12):28.[doi:10.3969/j.issn.1006-1959.2018.12.010]
　JIANG Yi-yao,WANG Kai,SHI Chao.Research Progress of Atrial Fibrillation Caused by Myocardial Fibrosis[J].Journal of Medical Information,2018,31(13):28.[doi:10.3969/j.issn.1006-1959.2018.12.010]
[2]张定欣,林先和.经食道三维超声在房颤二尖瓣结构变化对其 返流程度影响中的应用[J].医学信息,2018,31(12):76.[doi:10.3969/j.issn.1006-1959.2018.12.023]
　ZHANG Ding-xin,LIN Xian-he.Application of Transesophageal Three-dimensional Ultrasound in the Influence of Mitral Valve Structure Changes on the Degree of Reflux in Atrial Fibrillation[J].Journal of Medical Information,2018,31(13):76.[doi:10.3969/j.issn.1006-1959.2018.12.023]
[3]王淑娟,林祥灿.血浆NT-proBNP水平与同型半胱氨酸对 糖尿病合并心房颤动的相关性研究[J].医学信息,2018,31(14):169.[doi:10.3969/j.issn.1006-1959.2018.14.053]
　WANG Shu-juan,LIN Xiang-can.Correlation between Plasma NT-proBNP level and Homocysteine in Patients with Diabetes Mellitus Complicated with Atrial Fibrillation[J].Journal of Medical Information,2018,31(13):169.[doi:10.3969/j.issn.1006-1959.2018.14.053]
[4]陶春艳.柔性护理在胺碘酮治疗心房颤动护理中的应用研究[J].医学信息,2018,31(24):154.[doi:10.3969/j.issn.1006-1959.2018.24.046]
　TAO Chun-yan.Application of Flexible Nursing in the Treatment of Atrial Fibrillation with Amiodarone[J].Journal of Medical Information,2018,31(13):154.[doi:10.3969/j.issn.1006-1959.2018.24.046]
[5]赵殿儒,祁景蕊.不同剂量瑞舒伐他汀对急性冠脉综合征患者心功能和炎症因子的影响[J].医学信息,2019,32(01):148.[doi:10.3969/j.issn.1006-1959.2019.01.046]
　ZHAO Dian-ru,YAN Jing-rui.Effects of Different Doses of Rosuvastatin on Cardiac Function and Inflammatory Factors in Patients with Acute Coronary Syndrome[J].Journal of Medical Information,2019,32(13):148.[doi:10.3969/j.issn.1006-1959.2019.01.046]
[6]镡子鸣,叶怀阔,任长杰.超敏C反应蛋白及妊娠相关血浆蛋白A预测再发急性冠脉综合征的临床价值[J].医学信息,2019,32(08):173.[doi:10.3969/j.issn.1006-1959.2019.08.055]
　TAN Zi-ming,YE Huai-kuo,et al.Clinical Value of High-sensitivity C-reactive Protein and Pregnancy-associated Plasma Protein A in Predicting Recurrent Acute Coronary Syndrome[J].Journal of Medical Information,2019,32(13):173.[doi:10.3969/j.issn.1006-1959.2019.08.055]
[7]梁道博,姚卜飞,夏双燕.氯吡格雷联合阿司匹林治疗急性冠脉综合征疗效与 安全性的Meta分析[J].医学信息,2019,32(11):76.[doi:10.3969/j.issn.1006-1959.2019.11.021]
　LIANG Dao-bo,YAO Bu-fei,XIA Shuang-yan.Meta-analysis of the Efficacy and Safety of Clopidogrel Combined with Aspirin in the Treatment of Acute Coronary Syndrome[J].Journal of Medical Information,2019,32(13):76.[doi:10.3969/j.issn.1006-1959.2019.11.021]
[8]古俊楠,张牧秋,王建强,等.可穿戴设备在心房颤动诊治中的应用[J].医学信息,2019,32(15):34.[doi:10.3969/j.issn.1006-1959.2019.15.012]
　GU Jun-nan,ZHANG Mu-qiu,WANG Jian-qiang,et al.Application of Wearable Devices in the Diagnosis and Treatment of Atrial Fibrillation[J].Journal of Medical Information,2019,32(13):34.[doi:10.3969/j.issn.1006-1959.2019.15.012]
[9]刘 瑜,王建强,古俊楠,等.房颤合并功能性二尖瓣返流研究[J].医学信息,2019,32(15):51.[doi:10.3969/j.issn.1006-1959.2019.15.017]
　LIU Yu,WANG Jian-qiang,GU Jun-nan,et al.Study on Atrial Fibrillation Combined with Functional Mitral Regurgitation[J].Journal of Medical Information,2019,32(13):51.[doi:10.3969/j.issn.1006-1959.2019.15.017]
[10]朱文书,张理想,游杨杨,等.长链非编码RNA MIAT表达水平与心房颤动导管消融术后复发的关系[J].医学信息,2021,34(04):75.[doi:10.3969/j.issn.1006-1959.2021.04.020]
　ZHU Wen-shu,ZHANG Li-xiang,YOU Yang-yang,et al.Relationship Between the Expression Level of Long Non-coding RNA MIAT and Recurrence After Catheter Ablation of Atrial Fibrillation[J].Journal of Medical Information,2021,34(13):75.[doi:10.3969/j.issn.1006-1959.2021.04.020]
[11]王建强,刘 瑜,张牧秋,等.房颤伴ACS患者经皮冠状动脉介入术后抗栓研究[J].医学信息,2019,32(14):35.[doi:10.3969/j.issn.1006-1959.2019.14.013]
　WANG Jian-qiang,LIU Yu,ZHANG Mu-qiu,et al.Study on Antithrombotic after Percutaneous Coronary Intervention in Patients with Atrial Fibrillation and ACS[J].Journal of Medical Information,2019,32(13):35.[doi:10.3969/j.issn.1006-1959.2019.14.013]

更新日期/Last Update: 2019-07-01